drugset
Drugs / TAK-003
last change Jan 2023 re-read 2 minutes ago

TAK-003

also known as TDV

Vaccine

Investigated by
Takeda

Trials 1 · a red edge is where a trial was stopped

today NCT03525119 · Ph 3
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT03525119 May → Oct 2018 — Takeda Completed No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2022-11-22 Takeda Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration takeda.com ↗
2016-09-07 Takeda Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003) takeda.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as TAK-003 “A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV)...” PMID 36681529 ↗ Jan 2023
Known as TDV ClinicalTrials.gov intervention name — accepted as the source's own label NCT03525119 ↗
Modality Vaccine “a live-attenuated tetravalent dengue vaccine (TAK-003)” PMID 36681529 ↗ Jan 2023
Route Subcutaneous “TDV SC injection” NCT03525119 ↗